Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Francesca Bruce

Francesca Bruce has been writing news and analysis about all things affecting the pharmaceutical industry since 2008. She has paid special attention to policy and regulatory developments but particularly likes to write about market access and how medicines may  - or may not  -  make it to patients. She generally writes about Europe, but really enjoys uncovering news from further corners of the globe, especially Latin America and the Middle East.
Set Alert for Articles By Francesca Bruce

Latest From Francesca Bruce

Scotland Recommends Interim Funding For Regeneron/Sanofi’s Libtayo

Patient access schemes have helped the Scottish Medicines Consortium recommend rare disease products, including Regeneron/Sanofi’s Libtayo for skin cancer.

Europe United Kingdom

Meindert Boysen On What Companies Should Expect From NICE

In an exclusive interview, senior NICE director Meindert Boysen reveals the best advice he ever received and how companies whose products are under review can improve their chances of success.

Market Access Pricing Strategies

Novartis ‘Urgently’ Working To Improve Zolgensma Access Program

Criticism of Novartis/Avexis’s controversial lottery style managed access program for Zolgensma has come largely from Europe, while other countries in Latin America and Asia have been far more receptive.

Europe Gene Therapy

Luxturna & Crysvita Pioneer Scotland’s New Orphan HTA System

Novartis’s Luxturna and Kyowa Kirin’s Crysvita are the first drugs to be evaluated through Scotland’s new ultra-orphan process.

Europe United Kingdom

UK Urged To Fund Rare Disease Treatments Immediately

Genetic Alliance UK says companies should be clear about how they price rare disease treatments and that the government should explain how it assesses affordability.

Europe United Kingdom

Zolgensma ‘Lottery’ Attacked From All Sides

An unusual managed access program for Zolgensma designed by Novartis and AveXis has been attacked on ethical grounds, with critics claiming it does not properly allot the gene therapy to patients most in need. The companies have rejected the criticism, saying the program is fair and equitable.

Europe Belgium
See All
UsernamePublicRestriction

Register